key: cord-0872713-x4e65hu8
authors: Bhogal, Sukhdeep; Aladin, Amer I.; Wermers, Jason P.; Morrison, Natalie; Gray, Nathan; Waksman, Ron
title: Review of late-breaking trials from CRT 2022
date: 2022-05-16
journal: Cardiovasc Revasc Med
DOI: 10.1016/j.carrev.2022.05.017
sha: 639c87be4550b50349eea37d5468df19a266264f
doc_id: 872713
cord_uid: x4e65hu8

nan

The authors prospectively analyzed the study data from retrospectively acquired imaging and physiology data of study subjects with known or suspected CAD in whom invasive coronary angiography and FFR had been performed. The subjects, age >18 years, presented with stable angina pectoris, unstable angina pectoris, or non-ST-segment elevation myocardial infarction (NSTEMI) and underwent invasive FFR to assess a non-culprit narrowing in at least one coronary artery were enrolled. The key exclusion criteria were vessel diameter <2 mm, chronically occluded vessel, history of prior percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) in the target vessel, history of heart transplant or valve surgery, left ventricular ejection fraction (LVEF) <30%, Thrombolysis in Myocardial Infarction (TIMI) flow grade ≤2, left main coronary artery stenosis >50% and presence of diffuse coronary disease. The co-primary endpoints were sensitivity and specificity of AutocathFFR per vessel compared to invasive FFR. To assess the repeatability of the AutocathFFR measurements, manually identified lesions were analyzed three times by different operators. To further study the reproducibility of the AutocathFFR results, all cases (based on the automated software selection) were analyzed twice.

A total of 297 subjects were enrolled. Baseline characteristics of the patient population included mean age of 63.7 ± 10.0 years, with a majority (78.8%) being male. The most common presentation was unstable angina (27.6%), followed by NSTEMI (18.5%).

The study demonstrated that the accuracy of AutocathFFR in comparison to invasive FFR (304 vessels) was 93.7%, with an area under the curve (AUC) of 0.93 (0.88-0.97). The study successfully achieved the primary endpoints of sensitivity and specificity of 91.3% and 94.5%, respectively, beyond the prespecified target of 75%. When assessing the AuthocathFFR performance in the gray zone areas (FFR 0.77-0.87) in 136 vessels, the accuracy, sensitivity, and specificity were even better and remained above 93%. The repeatability of the study assessed by three different operators was 0.85±0.06, 0.85±0.05, and 0.86±0.05, p=0.436. Additionally, the reproducibility was noted to be 100%.

The AutocathFFR computation takes only 45 secs and is hands free per lesion, said Dr. Garcia-Garcia. It requires only two views per lesion and is not adenosine dependent like invasive FFR.

The study concluded that AutocathFFR has an excellent diagnostic performance against invasive FFR with 100% reproducibility and excellent repeatability. PzF plus 14 days DAPT and 501 were given a standard DES with 3 to 6 months DAPT, with similar weightings for age, gender, and smoking status. They had an even distribution for other conditions such as diabetes, hypertension, prior heart failure, and previous MI. Of the COBRAplus-short-DAPT group, 27% were indicated for PCI with acute coronary syndrome and 73% with chronic coronary syndrome, versus 32% and 68%, respectively, in the DES-plus-standard-DAPT group. Radial and femoral access was performed evenly between the two groups.

One component of the co-primary endpoint, BARC class ≥2 bleeding after hospital discharge or after 14 days (whichever is later), was seen in 7.79% of those given the COBRA plus short The study showed that treatment with the Cobra PzF stent was found to be safe, with ST rates considerably lower than those seen in earlier trials with high bleeding risk patients, despite vs. DP-EES 16.5%; p=0.136). The trial also showed significantly lower rates of ID-TLR at 2 and 3 years in the BP-SES arm, but while the rate was still numerically lower in the BP-SES arm at 5 years, the significance had disappeared (BP-SES 5.9% vs. DP-EES 7.7%; log-rank p=0.202).

TVMI was significantly lower at 5 years in patients receiving BP-SES (7.3%) than in the DP-J o u r n a l P r e -p r o o f EES arm (11.5%; p=0.02). The same was true of very late (1-5 years) ST (0.1% vs. 1.0%; p=0.047) and late or very late (30 days through 5 years) definite or probable ST (0.3% vs. 1.6%; p=0.021).

Dr. Kandzari concluded that the findings of the study affirm the durability of longer comparative outcomes with the ultrathin-strut BP-SES and demonstrate superiority in late ischemic events.

Presenter: Carlos Collet, MD, PhD The results were reported by Carlos Collet, MD, from the Cardiovascular Center OLV-Aalst, Belgium [6] . The study was sponsored by the University of Brussels and received an unrestricted gran from Abbott Vascular.

Cardiac stress tests remain the cornerstone for suspected CAD, but this kind of testing has been shown to have moderate accuracy in detecting CAD. It detects myocardial ischemia, typically due to epicardial narrowing. The presence of microvascular disease can also induce alterations of non-invasive tests, which can be interpreted as false-positive tests.

The current study, therefore, sought to determine the false discovery rate of exercise stress tests using an interventional diagnostic procedure (IDP) with indexes of epicardial FFR and microvascular resistance (index of microcirculatory resistance [IMR]) as clinical references. Its goal was to determine the false discovery rate of cardiac exercise stress tests with both FFR and IMR as references, and to assess the impact of an interventional diagnostic procedure with IMR on the accuracy of cardiac stress test.

The multicenter, investigator-initiated, prospective study enrolled 107 patients with an intermediate pre-test probability of CAD and positive exercise stress tests, who were referred for conventional angiography. The patients' mean age was 62.1±8.7 years, the majority (78%) were male, 55.1% had hypertension, 17% had diabetes mellitus, and 66% had Canadian In the exercise tests, average time to ST-deviation was 5.8 ± 1.3 minutes, with a mean ST depression of 1.6 ± 0.1 mm, while the mean diameter stenosis was 37.2% ± 14.4%, FFR 0.84 ± 0.06, IMR 15.24 ± 9.12, and coronary flow reserve 2.54 ± 1.02. In patients with positive exercise test, 34% had epicardial disease with diameter stenosis >50%, 46% had normal FFR and IMR, 17% had microvascular disease and only 3% had abnormal FFR and IMR. The false discovery rate, defined as the number of false positives divided by all positives, was highest with IMR at 79%, followed by FFR at 63% and quantitative coronary angiography (QCA) at 60%. The lowest false discovery rate was with the combined FFR and IMR reference standard, at 46% (p < 0.05 compared to QCA). The prevalence of abnormal IMR in ischemia with no obstructive coronary arteries (INOCA subgroup) was 27%.

The key limitation of study was that diagnostic performance in terms of sensitivity and specificity could not be evaluated, as patients with negative stress test were not enrolled. 

Bethesda, Maryland, and MedStar Washington Hospital Center, the authors noted that cerclage is a catheter procedure performed under X-ray and ultrasound guidance without surgery. The trial evaluated the safety and feasibility of TMCV in patients with MR and either heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF), and subjects with prior transcatheter edge-to-edge repair but persistent or recurrent symptomatic MR. The prospective, multicenter, single arm, open-label study was funded by the NIH. The primary endpoint was technical success measured at exit from the catheterization laboratory, while the secondary outcome was procedural success at 30-day follow-up and no TMCV-related serious adverse device effects. Other measures at follow-up included heart failure quality-of-life assessments and serial imaging with echocardiography and cardiac computed tomography (CT).

The study enrolled 19 subjects from 3 sites who underwent cerclage. The key inclusion criteria included age ≥ 21 years with symptomatic functional MR on optimal medical therapy for at least 1 month, LVEF ≥ 20%, and suitable coronary venous anatomy for TMCV based on preprocedural cardiac CT or invasive coronary venogram. Subjects with a prior history of TEER were enrolled if they had undergone the procedure at least 30 days previously. The mean age of the patients was 73 years, and a majority (63%) were female. Of the study population, 37% had HFpEF and 63% had HFrEF, while ischemic cardiomyopathy was present in 26% and nonischemic in 74% of patients.

The primary endpoint was met in 17/19 subjects. The team noted that cerclage was aborted in one subject without sequelae because the chosen intramyocardial trajectory was too close to the left anterior descending artery and caused compression upon tensioning. The subject completed 30-day follow-up and then re-enrolled under a new subject identifier and underwent successful implantation. In a second patient, cerclage was also aborted without sequelae because a suitable intramyocardial trajectory could not be found, presumably because of fibrosis from prior surgery.

The secondary endpoint of procedural success was met in 16/19 subjects, adding that in addition to the two patients who did not meet the primary endpoint, the device fractured in one subject between hospital discharge and 30 days. In this patient, there were no complications related to device fracture other than loss of efficacy.

group. Discharge directly home without TIA or stroke was far more common in the transcaval arm (87.8% vs 62.3%).

To account for baseline changes, inverse-propensity weighting (doubly robust) analysis was performed, and the results with regards to in-hospital and 30-day stroke, direct discharge to home, and discharge to home without stroke and hemoglobin drop favored the transcaval group.

Dr. Lederman said the analysis shows that compared with transaxillary access, transcaval access resulted in lower stroke rate (similar to that of transfemoral access), comparable or lower bleeding, comparable vascular complications, more discharge to home without stroke, and fewer complications than in previously reported studies.

He concluded that given superior neurovascular outcomes and ergonomics for the operator, transcaval access appears to be an attractive, first-choice non-femoral access route for TAVR.

Hands Free Artificial Intelligence Based Angiographic Derived Fractional Flow Reserve Assessment

Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE)

Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE)

Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents for Coronary Revascularization: Final 5-year Outcomes from the Randomized BIOFLOW V Trial

bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial

Redefining the Diagnostic Performance of non-invasive Stress Tests for the Detection of Coronary Artery Disease

Transcatheter Aortic Valve Replacement in Low-Risk Patients with Symptomatic Severe Aortic Stenosis: 4 -Years Results from the LRT Trial

Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis

Transcatheter Mitral Cerclage Ventriculoplasty: Results from the First-in-Man Early Feasibility Trial

Real-world Outcomes with WATCHMAN FLX: Early Results from SURPASS

Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial

Transcaval versus transaxillary TAVR in contemporary practice: a propensity weighted analysis

Transcaval Versus Transaxillary TAVR in Contemporary Practice

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector. All other authors -None.

Robert J. Lederman, MD, of the National Heart, Lung and Blood Institute, presented data from eight experienced centers that contributed data to the TVT Registry between 2017 and 2020 [12] .The results were later published in JACC: Cardiovascular Interventions [13] .Non-femoral TAVR access confers a high risk of mortality and complications. Transaxillary access has been widely adopted as an alternative access, and transcaval access has a reputation for complications since its original 2017 Investigational Device Exemption trial. The new analysis sought to determine whether transcaval complications are any worse than transaxillary complications and whether the stroke rate is comparable between the two approaches. Transcaval access was used in 238 TAVR patients and transaxillary in 106, and these results were compared to those from 7,132 who underwent transfemoral TAVR. Most baseline characteristics were similar between patients undergoing transaxillary and transcaval access, but there were a few differences specifically, transcaval patients were more likely to be female (56.3% vs. 43.4%), minority (20.9% vs. 9.1%), have private insurance (56.3% vs. 42.0%) and have moderate to severe chronic lung disease (40.3% vs. 34.0%). Procedural characteristics showed several differences. In the transcaval arm, moderate sedation was used more often (45.4% vs. 14.2%), fluoroscopy time was longer (33.60 minutes vs. 24.90 minutes), contrast volume was higher (130.5 ml vs 101.3 ml), and all transcaval procedures were fully percutaneous as compared to 84% of transaxillary procedures.In-hospital stroke or transient ischemic attack (TIA) was less common after transcaval compared to transaxillary (2.5% vs. 13.2%) and the same was true at 30 days (2.9% vs. 13.2%). Major or life-threatening bleeding was comparable between the two (10.1% vs. 13.2%). All of these rates were higher with the alternative access compared with the transfemoral approach (stroke/TIA inhospital 1.7% and 2.1% at 30 days). Similarly, major or life-threatening bleeding was lower in transfemoral cohort, 3.5% at 30 days, compared to other two cohorts. The average length of stay (LOS) was slightly better in transcaval group (5.6 days vs 6.4 days) compared to transaxillary J o u r n a l P r e -p r o o f